Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1E7V

Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine

Summary for 1E7V
Entry DOI10.2210/pdb1e7v/pdb
DescriptorPHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT, 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE (3 entities in total)
Functional Keywordstransferase, secondary messenger generation pi3k, pi 3k, ly294002
Biological sourceSUS SCROFA (WILD BOAR)
Total number of polymer chains1
Total formula weight110259.90
Authors
Walker, E.H.,Pacold, M.E.,Perisic, O.,Stephens, L.,Hawkins, P.T.,Wymann, M.P.,Williams, R.L. (deposition date: 2000-09-08, release date: 2000-11-17, Last modification date: 2023-12-13)
Primary citationWalker, E.H.,Pacold, M.E.,Perisic, O.,Stephens, L.,Hawkins, P.T.,Wymann, M.P.,Williams, R.L.
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.
Mol.Cell, 6:909-919, 2000
Cited by
PubMed Abstract: The specific phosphoinositide 3-kinase (PI3K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways. The X-ray crystallographic structures of PI3Kgamma bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compounds fit into the ATP binding pocket. With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain. Surprisingly, LY294002 and the lead compound on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind PI3K in remarkably different orientations that are related to each other by 180 degrees rotations. Staurosporine/PI3K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes. These results provide a rich basis for development of isoform-specific PI3K inhibitors with therapeutic potential.
PubMed: 11090628
DOI: 10.1016/s1097-2765(05)00089-4
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

240971

数据于2025-08-27公开中

PDB statisticsPDBj update infoContact PDBjnumon